Agenus (NASDAQ:AGEN) Issues Quarterly Earnings Results

Agenus (NASDAQ:AGEN) posted its earnings results on Monday. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.10 by ($1.08), Zacks reports. Agenus had a net margin of 50.49% and a negative return on equity of 29.79%. The company had revenue of $33.70 million during the quarter, compared to the consensus estimate of $129.50 million.

Agenus Price Performance

Shares of Agenus stock traded up $0.11 during trading on Wednesday, hitting $3.55. The stock had a trading volume of 109,286 shares, compared to its average volume of 774,293. The business has a fifty day moving average of $3.72 and a two-hundred day moving average of $3.67. The firm has a market cap of $136.24 million, a P/E ratio of 2.22 and a beta of 1.60. Agenus has a fifty-two week low of $2.71 and a fifty-two week high of $7.34.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on AGEN shares. Zacks Research lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday. Wall Street Zen upgraded Agenus from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Agenus currently has a consensus rating of “Hold” and an average target price of $14.50.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Invesco Ltd. bought a new position in shares of Agenus during the 1st quarter valued at $88,000. AQR Capital Management LLC lifted its holdings in Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after purchasing an additional 427,604 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Agenus in the 1st quarter worth approximately $58,000. JPMorgan Chase & Co. boosted its position in Agenus by 608.0% during the second quarter. JPMorgan Chase & Co. now owns 78,637 shares of the biotechnology company’s stock worth $359,000 after purchasing an additional 67,530 shares during the period. Finally, Marshall Wace LLP acquired a new position in Agenus during the second quarter valued at approximately $1,976,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.